#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma
Click to read this study in the Journal of Clinical Oncology.
Click to read this study in the Journal of Clinical Oncology.
Click to read the study in JAMA Dermatology.
1. Older age, progressive disease status, diagnosis of acute myeloid leukemia, non-Hodgkin lymphoma, or plasma cell neoplasms, and severe or ...
1. In a retrospective review of over 1500 Hodgkin lymphoma (HL) survivors, the risk of coronary heart disease (CHD) was ...
1. In this study, patients who received treatment for Hodgkin’s Lymphoma had a 3 to 6 fold increased incidence of ...
1. In patients with negative PET scans after 3 cycles of chemotherapy, 3-year progression free survival was slightly better among ...
1. In this phase 3 randomized controlled clinical trial, brentuximab vedotin significantly improved progression-free survival in Hodgkin’s lymphoma patients at ...
Originally published by Harvard Health. What Is It? Hodgkin lymphoma is a cancer of the immune system. It is also called ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.